Definium's LSD-Based Treatment Shows Positive Results in Second Anxiety Trial
Definium Therapeutics (NASDAQ:DFTX) has reported a second successful Phase 3 trial for its LSD-based medication, DT120, used to treat generalized anxiety disorder. The drug demonstrated a significant placebo-adjusted improvement of 5.1 points on the Hamilton Anxiety Rating Scale over 12 weeks in patients receiving a 100-microgram dose. This follows another strong result from an earlier trial and positions Definium for potential FDA approval. The psychedelic sector has historically shown correlated stock movements, with positive data from one company often boosting others. Compass Pathways' recent success had previously triggered gains across the sector. Definium's results reinforce a broader scientific argument that classic psychedelics can offer lasting mental health benefits through mechanisms distinct from traditional drugs like SSRIs. Hedge fund interest in DFTX has grown, with institutional holdings increasing significantly between Q1 and Q2 2026. The company is now preparing for its pre-NDA meeting as the next step toward regulatory submission.
Topics: FDA approval pathway generalized anxiety disorder LSD psychedelics sector